Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Inmagene and HutchMed Start Global Trial of BTK Inhibitor

publication date: Aug 9, 2022

Inmagene Biopharma and HutchMed announced that the first person was dosed in a global Phase I trial of their partnered Bruton Tyrosine Kinase inhibitor. IMG-004 is a non-covalent, reversible, third-gen BTK inhibitor being developed to treat immunological diseases. In early 2021, Shanghai’s Inmagene in-licensed global rights to four novel pre-clinical HutchMed immunological candidates in a deal worth up to $920 million. Both companies are headquartered in Shanghai; Inmagene also has operations in San Diego. Founded in 2019, Inmagene has raised $140 million in three venture capital rounds. More details....

Stock Symbols: (NSDQ/AIM:​ HCM; HK:​ 13)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022